Business Wire

Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today ...
Business Wire

First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today ...